Cardiac Progenitor Cell Therapy for Myocardial Infarction Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular diseases, such as myocardial infarction, often result in loss of cardiomyocytes, cardiac scar formation, and eventual heart failure, with limited effectiveness in repairing or regenerating injured heart tissue.
Innovation Solution
Isolation and cultivation of a clonal population of cardiac progenitor cells, specifically Sca-1 positive, CD45 negative cells, which express Isl1, GATA4, and NKX2.5, and their administration to injured hearts, optionally with angiogenesis promoting factors like IL-15, FGF, or VEGF, using a matrix comprising acrylated hyaluronic acid (AcHyA) to promote survival and differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for myocardial infarction, then immediate medical intervention is provided, but cardiomyocytes are lost and cardiac scar formation occurs
Solution Approach 1:
The patent extracts and isolates specific cardiac progenitor cells (Sca-1 positive, CD45 negative) from heart tissue to create a purified cell population for therapy, separating the therapeutic agents from the harmful inflammatory environment that causes cardiomyocyte loss
Solution Approach 2:
The patent changes the biological parameters of the treated tissue by introducing exogenous growth factors (FGF, VEGF, IL-15) and using acrylated hyaluronic acid matrix to alter the regenerative capacity of the heart tissue, transforming the pathological state into a regenerative state
2Quantity of substance
If cardiospheres are cultured to expand cell population, then more cells are available for therapy, but culture time and complexity increase
Solution Approach 1:
The patent performs preliminary isolation and characterization of cardiac progenitor cells with specific markers (Sca-1+, CD45-, Isl1+, GATA4+, NKX2.5+) before therapy, prepping the cells in advance to ensure they are ready for immediate administration without requiring prolonged in-vivo culture expansion
Solution Approach 2:
The patent uses acrylated hyaluronic acid matrix as a synthetic extracellular matrix copy that mimics the natural cardiac environment, providing structural support and biochemical cues that enable cell survival and differentiation without requiring complex long-term culture conditions
3Productivity
If angiogenesis promoting factors are administered, then blood vessel formation is enhanced, but treatment complexity increases
Solution Approach 1:
The patent merges multiple therapeutic components into a single composite treatment: cardiac progenitor cells are co-administered with angiogenesis promoting factors (FGF, VEGF, IL-15) and acrylated hyaluronic acid matrix in a unified therapeutic formulation, simplifying the treatment protocol while achieving synergistic effects
Solution Approach 2:
The acrylated hyaluronic acid matrix serves multiple functions simultaneously: it provides structural scaffold for cell attachment, delivers growth factors through controlled release, reduces inflammation, and promotes both angiogenesis and cardiomyocyte regeneration, eliminating the need for separate treatment protocols
Data Source
AI summary
Provided herein are compositions and methods for isolating and culturing cardiac progenitor cells, and for improved transplantation.